ArticleBMC microbiology2025
High alcohol-producing Escherichia coli causes obesity and steatotic liver disease in a non-alcoholic cohort -a preclinical study.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The gut is guilty! Will legalomics transform forensic and legal psychology?Frontiers in psychology · 2026Article
- Integrated microbial and endocrine signatures of obesity:Frontiers in microbiomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a global epidemic and multifactorial disease caused by alcohol consumption, a sedentary lifestyle, and genetic and environmental factors. Analyses of gut microbial diversity in obese individuals have been conducted earlier. Unlike non-alcoholic fatty liver diseases, the mechanistic insights into the role of gut microbiota in the development of obesity remain poorly understood. Deciphering the mechanism underlying bacterial-induced obesity will help in targeted therapeutic approaches. We demonstrated bacteriophage therapy as a new offering to treat obesity and hepatic steatosis.
methodsStool samples from the non-alcoholic obese cohort (BMI > 27 kgm−2) were cultured to analyze gut microbiota. Bacteria were grouped into clusters based on whole-genome-based genotyping. The most predominant, high alcohol-producing E. coli strain, GNBHU03 (ECGNBHU03), was selected for further studies. Genome sequencing and subsequent analyses were performed to understand the pathogenesis of ECGNBHU03. Further, an obesity model was developed by administering ECGNBHU03 into male mice. The induced obesity and liver steatosis were evaluated using weight measurements, blood biochemical tests, and changes in the liver histology. Cocktails of three ECGNBHU03-specific bacteriophages were used to eradicate the ECGNBHU03; blood biochemical tests and histological studies evaluated the effect of eradicating ECGNBHU03 from the gut.
resultsEscherichia coli was predominantly detected in the feces of 95.65% of individuals compared to the control group (non-alcoholic healthy cohort with BMI 18.5–22.9 kgm−2). Whole-genome-based genotyping generated five groups. The high alcohol-producing Escherichia coli strain, GNBHU03, was enriched in the gut microbiota of non-alcoholic obese individuals. Genomic analyses showed that GNBHU03 harbours different virulence genes, specifically lpf and hlyE associated with increased intestinal colonization and permeability. In ECGNBHU03-fed mice, colonization with ECGNBHU03 induced obesity, hepatic steatosis, and systemic inflammation, evident by elevated serum aminotransferases, endotoxins, pro-inflammatory cytokines, triglycerides, cholesterol levels, and liver steatosis. Further, targeted bacteriophage therapy effectively eradicated strain ECGNBHU03, reversing obesity and hepatic steatosis.
conclusionsThis study highlights the complexity of obesity’s etiology and, for the first time, provides mechanistic insights into obesity and liver dysfunction caused by the high ethanol-producing E. coli strain GNBHU03. Notably, targeted bacteriophage therapy could be a promising strategy to mitigate obesity, offering a novel approach to obesity treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.